Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count

Fig. 2

CAR-T manufacturing data of patients participating in phase I clinical trials. The figure shows the PBMC composition, CAR expression, and CAR-T cell expansion data of 26 patients who participated in CD19 and BCMA CAR-T phase I clinical trials. a Heatmap analysis of CD14 percentage in patients’ PBMC and CAR-T expansion days required to reach the requested dosage. The left column shows the CD14 percentage (1.04–56.29%) in PBMC from high to low before cryopreservation, and the right shows CAR-T expansion days (4–11) of the corresponding patient. b CAR-T cell expansion duration of each patient was plotted against CD14 expression levels in PBMC. Among all patients, CAR-T cells (01-001-CHFY, 02-01-004-LUYN, and 03-002-009-GAXF) took the longest to expand. Expansion duration: the days between the completion of retroviral transduction and the filling of the CAR-T product. c Individual expansion rate of CAR-T cells of all patients. The expansion curve of T cells from patients (01-001-CHFY, 02-01-004-LUYN, and 03-002-009-GAXF) are marked with black, blue, and purple, respectively. d CAR-T cell expansion duration divided by different CD3+ T cell isolation buffers. e CAR expression percentage in CD3+ cells of each patient was plotted against CD14 expression levels in PBMC. f CAR expression percentage in CD3+ cells was compared between groups of CAR-T cells selected with two isolation buffers

Back to article page